We report that 100% mice survival after tumor challenge is achieved with cytokine-engineered cells employing nonviral lipoplexes and without using viral vectors. We describe this effect with cytokine-secreting tumor cell vaccines, based on cell clones or fresh transfected cells. Tumor cells were transfected with murine granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-4 plasmids employing the cationic lipid DOTAP, were irradiated (150 Gy) and kept frozen until use. The transfection efficacy was analyzed by qRT-PCR and flow cytometry. Vaccination induced potent antitumor rejection, resulting in 100% mice survival. Furthermore, the antitumor immunity was long lasting, since a two-fold survival delay was observed in mice after tumor rechallenge (6 months later). While cell clones secreting GM-CSF were the most effective in wild-type tumor cell rejection, little or no effect was observed with clones secreting IL-4. We found similar antitumor efficacy employing fresh transfected cells by nonviral procedures, demonstrating that cells genetically modified by nonviral vectors (both clones and fresh transfected cells) are a safe and efficient tool for antitumor vaccines. These vaccines allow us to achieve the highest antitumor efficacy based on nonviral gene therapy techniques. In addition, the vaccination success with fresh transfected cells simplifies the procedure and provides new insights into the clinical application of nonviral gene therapy procedures.
T umor cells can be genetically modified for different purposes, for instance to express immunostimulatory substances (cytokines) that can stimulate the immune system against tumor cells.
1,2 This approach is based on the fact that in many cases tumor cells do not mediate immune system activation, although they do present tumor-associated antigens at the surface level. 3 The expression of certain cytokines by these tumor cells can stimulate the immune system, resulting in cell elimination by enhancing tumor immunogenicity with minimal systemic toxicity. 4 Certain immune reactions are involved in tumor rejection, such as ''cross-priming'' processes, 1, 5 or direct antigen presentation by vaccine cells, 6, 7 resulting in the activation of CD8+ cytotoxic T (CTL) and CD4+ helper T (Th) lymphocyte responses. 8 Cross-priming processes imply cellular antigen transfer from tumor cells to host antigen-presenting cells (APC) for processing and presentation. 9 This event has been shown to require T-cell help, 10 the presence of transporters associated with antigen presentation (TAP) in tumor cells 11 and
CD8a+ dendritic cells (DC). 12, 13 Another important point to be considered is that the immune response achieved by the vaccine depends on the immunostimulatory protein secreted by the cell vaccines. 1, 14, 15 Thus, the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 4 (IL-4) and others cytokines 1, 5 have been demonstrated to exert antitumor effects, but IL-8 has been described to act as a growth factor in human melanoma. 16 In the present study, we have chosen GM-CSF and IL-4 for their purported different roles in immune system stimulation. [17] [18] [19] Accordingly, GM-CSF induces high antibody titers and T-cell proliferation, 20 even after allogeneic T-cell-depleted bone marrow transplantation. 21 Cytokine IL-4 in turn promotes the development of Th 2 cells and increases the production of antibodies and MHC class I and ICAM-1 expression in transfected cells, 22 although it could suppress CTL activity. 8, 23 In addition, the combination of GM-CSF and IL-4 would be particularly beneficial, since both GM-CSF and IL-4 induce growth expansions of phenotypically and functionally different subpopulations of dendritic cells. 24 We expect the efficacy of vaccination to depend on the efficacy of gene transfer to cells. 25 Since nonviral vectors are growing in gene transfer efficiency, we hope that such vectors could be appropriate systems for transfecting cells mediating an effective antitumor response. It has previously been demonstrated that effective antitumor response against melanoma and other tumors can be observed employing viral vectors targeted to modified tumor cells. 26, 27 However, nonviral gene therapy has shown fewer approaches to cell vaccine applications. The aim of achieving similar antitumor responses with nonviral vectors is very important, since it allows the choice of using this safer antitumor therapy. 28 We therefore studied the effect of vaccination on syngeneic mice survival employing tumor cell clones and freshly transfected tumor cells producing GM-CSF or IL-4. Different doses of irradiated vaccines were employed (from 0.2 to 2 million cells per mouse), resulting in 80-100% mice survival with GM-CSF cytokine-producing cells, but not with IL-4. Our results suggest that vaccines based on nonviral gene therapy can be an efficient and safe procedure with possible future clinical applications.
Materials and methods

Plasmids
Plasmids containing murine GM-CSF or IL-4 genes, controlled by a cytomegalovirus promoter, were obtained from Dr A Koenig (Mologen, Germany). The mGM-CSF (425 bp) was inserted into a 3853 kb pRL-CMV-modified plasmid with resistance to Kanamycin, and mIL-4 (438 bp) in a pCDNA3 (5414 kb) with Neomycin-and Ampicillin-resistance genes.
The plasmids were amplified in Escherichia coli (DH5a) and purified with the Qiagen Maxi protocol kit (Izasa SA, Spain).
Animals
Male and female C57BL/6 mice (7-10 weeks old) were obtained from Harlan (France). The animals were housed four to five per cage under standard laboratory conditions.
B16 melanoma cells
B16 melanoma cells, selected by IJ Fidler from a murine melanoma, are syngeneic in C57BL/6 mice. Cells were grown in cell culture Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (FBS, Biomedia, France) and with penicillin (100 U/ml) and streptomycin (100 mg/ml) in a humidified incubator with 5% CO 2 at 371C. This adherent cell line was detached from the flasks with phosphate-buffered saline (PBS) and ethylenediaminetetraacetic acid (EDTA) 2 mM.
Cells were washed with PBS and inoculated in DMEM without antibiotics or FBS.
Cell transfection
The plasmid DNAs encoding for GM-CSF or IL-4 were transfected to cells using the cationic lipid vector DOTAP (Boehringer Mannheim-Roche, Diagnostics Roche, Spain). We employed a mass ratio of 4 : 1 (DOTAP:D-NA), which implies a molar ratio of 1.7 : 1 (N/P, N ¼ moles of nitrogen atoms in DOTAP and P ¼ moles of DNA phosphate groups). The DNA solution was prepared in PBS, and the DOTAP was prepared in endotoxin-free ultrapure water (MilliQ). An equal volume of each solution was mixed (500 mL final volume) and incubated 15 minutes before addition. In all cases, the lipoplex characterization was performed as previously described.
29 B16 cells were detached and seeded (3 million cells) in flasks (75 cm 3 ). When 70% confluence was reached (about 24 hours later), the cells were transfected with DOTAP/DNA complexes at 5 mg of DNA plasmid per ml of medium without serum. After 30 minutes of incubation at 371C, 10 mL of medium supplemented with 15% FBS was added (10% final FBS in DMEM). To select clones expressing GM-CSF or IL-4, 48 hours after transfection, cells were cultured in the presence of G418 (2 mg/mL), and 3 weeks later the resistant cells to G418 (Calbiochem, Spain) were harvested with PBS EDTA and seeded as 10 4 cells per Petri dish. Colonies were ringcloned, picked up, expanded and tested for cytokine production by quantitative RT-PCR and flow cytometry. For fresh transfection vaccination (transient expression), cells were irradiated 24 hours after transfection and frozen (À801C). For in vivo use, cells were warmed and two times washed in DMEM and in PBS to eliminate the freezing medium. Cells were counted and administered in DMEM/ PBS. Other samples (nontransfected) were also treated similarly. Aliquots were withdrawn to be analyzed by qRT-PCR and flow cytometry, employing GolgiStop solution (PharMingen, BD Biociencias, Spain). Other aliquots were used to evaluate the cell viability employing Calceine-AM (Live/Dead s viability/cytotoxicity from Molecular Probes, The Netherlands). Accordingly, cells were seeded (7,000 cells/microwell) in wells (96 microwells per plate) and cultured. At different times, the cell medium was removed to add 50 mL of a Calceine dilution in PBS (0.5 mL/mL PBS). Cells were incubated at 371C for 40 min, and the fluorescence (as a result of the cell esterase activity) was measured with a microplate cytofluorimeter (Cytofluor TM 2350 Millipore, Ex ¼ 485 nm, Em ¼ 530 nm).
Quantitative RT-PCR (qRT-PCR)
Primers for the cytokines as well as for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed using the computer program Primer Express (Applied Biosystems, Spain). The melting temperature (T m ) was close to 601C, and the amplicon lengths were under 100 bp; primers for murine GM-CSF, forward: 5 0 -3 0 TGGGCATTGTGGTCTACAGC, reverse: AAGGCCGGGTGACAGTGAT. For murine IL-4, forward: 5 0 -3 0 ACAGGAGAAGGGACGCCAT and reverse: CTGTGGTGTTCTTCGTTGCTG.
RNA was extracted from the cell samples employing the RNeasy purification Kit (Qiagen, Izasa SA, Spain). Reverse transcription of RNA to generate cDNA was carried out using the SYBR Green RT-PCR reagents kit (P/N 4310179, Applied Biosystems, Spain). The condi-tions for each 30 mL of final volume were: 3 mL 10 Â room temperature buffer, 6.6 mL 25 mM MgCl 2 , 6 mL 2.5 mM NTPs, 1.5 mL 50 mM Random Hexamers, 0.6 mL 20 U/mL RNase inhibitor, 0.75 mL 50 U/mL MultiScribe reverse transcriptase and 300 ng of total RNA. Samples were incubated at 251C for 10 minutes, at 481C for 30 minutes, and for 5 minutes at 951C to heat inactivate the reverse transcriptase.
PCR was performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The assay conditions for quantitative PCR (final volume of 50 mL) were: 2 mL of primer forward (10 mM), 2 mL of primer reverse (10 mM), 5 mL cDNA and 25 mL of 2 Â SYBR Green PCR master mix. The thermal cycling conditions included an initial step at 951C for 10 minutes, followed by 40 cycles at 951C for 15 seconds and 601C for 1 min. 30, 31 The method used for obtaining quantitative data of relative gene expression is the comparative Ct method (DDCt method) as described by the manufacturer. Ct is measured as the PCR cycle numbers at which the reporter fluorescent emission increases beyond a threshold level that is based on the background fluorescence of the system. The standard curves in qPCR were generated by cytokine plasmid 10-fold dilution from 10 À1 to 10 À6 ng. The Ct results were input in the standard curve with the quantity log.
An alternative approach for expressing qRT-PCR results is the use of the formula 2
ÀDDCt
, where:
Flow cytometry
For the detection of GM-CSF in transfected cells, we employed an immunostaining protocol. Briefly, cells were detached from the flasks and cultured under a solution (in DMEM 10% FBS) of GolgiStop (PharMingen, BD Biociencias, Spain), adding 4 mL per 6 Â 10 6 cells (1 million/mL) following the manufacturer's instructions. Cells were incubated at 371C for 4 hours under continuous agitation, followed by the IntraPrept Permeation Reagent protocol (PharMingen) employing 0.5 million cells, and 5 mL of GM-CSF or IL-4 antibodies coupled to fluorescein isothiocyanate (FITC) molecules (PharMingen). Cells were kept overnight in darkness until measurement was carried out using an FACScan flow cytometer (Becton-Dickinson).
Vaccination protocol
B16 cells were irradiated (150 Gy) before administration in vivo to prevent tumor proliferation of the vaccines. For cell clones vaccination, cells were immediately administered to mice after irradiation. For fresh transfection, cells were irradiated 24 hours after transfection, and afterwards were frozen at À801C until use.
Mice were vaccinated on days À21, À7 and +7, and the tumorigenic dose of 100,000 wild-type B16 cells was injected on day 0 in the opposite leg. The doses of vaccine employed in cell clones vaccination were 0.2 and 1 million cells, via an intradermal injection in the leg. A similar procedure was adopted (with 0.2 and 2 million cells) in the case of fresh transfected cells. Tumor development in vivo was monitored visually and analyzed for volume with a caliper in two dimensions on different days. The volume was calculated by the formula
, and A and B are the long and short diameters, respectively. Two blood extractions were performed in mice on days À1 and +15.
Radial immunodiffusion
For the measurement of IgM, IgG and IgG subtype levels, pooled sera from animals of each experimental group were used. Mice were bled by the tail vein into heparinized capillaries on days À1 and +15, followed by centrifugation at 160 g for 5 minutes and plasma collection. The assay consisted of a commercial radial immunodiffusion technique (the Binding Site, Birmingham, UK) with agarose plates containing monospecific antisera to mouse immunoglobulin isotypes and IgG subclasses. Serum samples were diluted according to the instructions of the manufacturer (1/2 for IgM and IgG3; 1/10 for IgG1, IgG2a and IgG2b), and an appropriate volume was dispensed into the precut wells. Immunoglobulins were allowed to diffuse for 96 hours, and precipitate ring diameters were measured by means of an eyepiece. The concentration was established on the basis of a correspondence table included in the kit. Controls were run in each assay to test for accuracy. In all instances, immunoglobulin levels in control samples were within the admissible range as stated by the manufacturer.
ELISA
The GM-CSF in the serum was measured with a murine GM-CSF kit following the instructions of the manufacturer (ParMingen, BD Biociencias, Spain). Serum-specific antibodies to tumor antigens were also measured by ELISA. Briefly, flat-bottom 96-well plates (Maxisorp, NUNC, USA) were coated with tumor membrane protein (TMP) 100 mL per well, obtained from B16 tumor cells as previously described. 32 The coating concentration of this ELISA antigen employed was 1 mg/mL in 50 mM CO 3 Na/ HCO 3 Na pH 9.6. The plates were sealed and incubated overnight at 41C. On the following day, the plates were washed with buffer (PBS containing 0.1% Tween 20) , and incubated at room temperature (RT) for 1 hour with blocking buffer (PBS with 1% BSA). Mice sera were diluted (1 : 20) in PBS containing 1% BSA and 0.1% Tween 20, added to the plates and incubated at 371C for 2 hours. To detect bound IgG, plates were incubated at RT for 1 hour with the secondary antibody (goat-anti mouse IgG-peroxidase, Caltag, USA), diluted 1 : 3000 in the same solution employed with mice sera. Finally, the substrate solution (30 mg/mL O-phenylenediamine dihydrochloride (OPD) with 0.03% H 2 O 2 in citrate buffer) was added to each well. The reaction was stopped by the addition of 1 N HCl. The results are expressed as the mean of the optical density (OD) at 492 nm.
Results
Cytokine expression in B16 clone cells
The B16 cell transfection with plasmids encoding for GM-CSF or IL-4 was developed using DOTAP lipoplexes. Transfected cells were selected from G418 resistance, and the expressions of cytokines were studied by qRT-PCR and flow cytometry. The highest and lowest gene expression clones were chosen for GM-CSF (cell clone 5 and 3) or IL-4 (cell clone 3 and 1) from among the cell clones analysed for each cytokine. Figure 1 shows the qRT-PCR results of these selected clones. For in vivo vaccination, both high and low cytokine expression clones were chosen. Since cell irradiation is a necessary condition for tumor vaccination, we also evaluated the effect of irradiation on cytokine gene expression. Thus, after 48 hours of cell irradiation (150 Gy), we performed RT-PCR quantification of the cytokines. The values resulting from the samples (Ct) were referring to a housekeeping gene (GAPDH) and treated mathematically via an exponential formula (2
ÀDDCt
, see also Materials and methods). In all cases, there was a decay in RNA production after cell clones irradiation, although these finals amounts were sufficient to mediate antitumor response as observed in our studies. The flow cytometry results based on intracellular immune labeling of the cytokine indicate cytokine production by clones, and confirmed the GM-CSF qRT-PCR results observed from low and high expression clones (data not shown).
We also studied cell viability after irradiation using a live/dead protocol. Cell viability persisted until day 10 and then decayed, ending approximately on day 21 (data not shown). These results suggest that cell survival after irradiation is long enough to allow a sustained period of local cytokine production after in vivo administration.
Vaccination with genetically modified cell clones
Vaccination was performed at two different doses of 0.2 and 1 million cells per mouse (intradermal injection in 0.1 mL volume). High and low cytokine expression clones as well as nontransfected cells and vehicle (DMEM) were used. The vaccination doses were administered on days À21, À7 and +7 with respect to tumor transplant in the opposite leg with 100,000 wild-type tumor cells (day 0). The results indicate that 100% mice survival was achieved in the group vaccinated with cell clones secreting high levels of GM-CSF (Fig 2a and b) . In addition, this effect was dose-dependent, since lower and higher doses (0.2 and 1 million cells/mouse), respectively, mediated 80% (Po.005) and 100% (Po.005) final mice survivals -the animals remaining tumor free. However, when mice were vaccinated with genetically modified cells expressing IL-4 cytokine, no effect on mice survival was observed, and all mice died spontaneously. Interestingly, increased survival was also observed in mice groups treated with GM-CSF plus IL-4-modified cells, although to a lesser extent (40% Po.005, and 80% Po.005, for 0.2 and 1 million total cell dose, respectively). It should be pointed out that in these cases, mice were vaccinated with 50% of GM-CSF-secreting cells plus 50% of IL-4-secreting cells. No increased survival was observed (Figure 2c and d) in the group of unvaccinated mice, or in animals vaccinated with B16 wild-type cells (not Regardless of the cell vaccine used, many vaccinated animals developed a vitiligo reaction, although not all of them remained tumor free until the end of the observation period. In most cases, vitiligo was located on the snout, although some animals exhibited extended reactions over the body.
Second exposure to tumor challenge in mice vaccinated with cell clones
The survivors from the above experiment were used to evaluate the persistent protective effect of vaccination. At 6 months after the first tumor cell challenge, a second injection with 10 5 wild-type B16 cells (0.1 ml intradermally) was administered in the leg opposite to the vaccines injection leg in these groups. An additional unvaccinated group of mice of similar age and sex was employed as control. No additional vaccination was administered to formerly vaccinated mice before tumor cells administration. Tumor development in the control group was greater than in mice vaccinated 6 months previously, showing a mean tumor volume of 2497.6 mm 3 by day 18, versus 114.2 and 109.9 mm 3 for the GM-CSF and GM-CSF/IL-4 groups, respectively. Furthermore, the survival results show (Fig 3) that vaccination increased mean survival two-fold, resulting in a 20% final survival rate at day +90 (Po.0001 for GM-CSF clone and Po.001 for GM-CSF/ IL-4 clones).
Immune response to vaccination with cell clones
Since most antibodies in the plasma are produced by B cells and immunoglobulin subtypes undergo isotype switching directed by cytokines, in the present study, we analyzed the immunoglobulin subtypes to determine the mainly activated pathways (Th1 or Th2) following in vivo vaccination. Thus, we could expect that IL-4 (secreted by Th2 cells) induces switching to IgG1, whereas cytokines secreted by Th1 cells preferentially induce switching to IgG2a and IgG3 33, 34 Accordingly, blood samples from mice were obtained on days À1 and +15 from tumor challenge. The analysis of total IgG, IgG subtypes and IgM from mice vaccinated with cell clones was carried out by radial immunodiffusion. The results showed that vaccination with low cytokine-expressing cell clones yielded a signal (data not shown) similar to that of nontransfected cells (control group). However, IgG1 and IgG2b from mice vaccinated with high cytokine-producing clones showed significant values (Figure 4) . A sixfold increase in IgG1 was observed at day 15, after vaccination with 0.2 million GM-CSF or GM-CSF/IL-4-producing cells per dose (Figure 4a) . At a vaccination dose of 1 million GM-CSF/IL-4-producing cells, the levels of IgG1 at days À1 and +15 increased up to four and 11 times, respectively (Figure 4b ). Similar differences were observed with IgG2b, although to a lesser extent (Fig 4c and d) . Accordingly, at a dose of 1 million (Fig 4d) , the signal from the GM-CSF/IL-4 vaccination group doubled to that of the B16 control cells, whereas no clear differences between samples were recorded with 0.2 million cells (Figure 4c ). Vaccinated animals with cells not genetically modified showed a significant decay in IgG3 levels at day +15 (data not shown). However, results from vaccination with GM-CSF or IL-4 clones showed sustained levels of IgG3 and IgG2a when Nonviral vector-mediated cell vaccines I Moret-Tatay et al using high secreting clones (data not shown). No significant differences were recorded when vaccinating with 0.2 million cell clones (data not shown). In the case of IgM, at a dose of 1 million cells/mouse, similar results were obtained for high and low GM-CSF plus IL-4-secreting cell clones, with values three-fold to those recorded in the control group (data not shown). The specificity of serum immunoglobulins against tumor membrane proteins derived from B16 tumor cells was confirmed by ELISA (Fig 5) . Cell clones producing GM-CSF showed the highest ELISA optical density values, and these values increased significantly from day À1 to day +15 from tumor injection.
Vaccination with freshly transfected GM-CSF cells
Vaccinations with cell clones producing high levels of GM-CSF are highly successful in terms of tumor protection. However, this process implies long periods of time for clone selection and amplification, thus limiting its interest for clinical application. It is clearly necessary to achieve similar results in alternative shorter procedures. In the present study, we therefore evaluated the efficacy of employing cells freshly transfected (transient production), irradiated and stored frozen until vaccination. Based on the clone vaccination results, we established a vaccination protocol employing autologous tumor cell vaccines engineered to secrete GM-CSF by means of nonviral fresh transfection (DOTAP/DNA lipoplexes). In these experiments, vaccination was performed using 0.2 or 2 million viable cells (cell viability decayed to 80% after irradiation, freezing and thawing, as determined by Trypan blue exclusion). Post-transfection cell expression of GM-CSF was determined by two procedures, qRT-PCR and flow cytometry. The qRT-PCR results were extrapolated into standard regression curves obtaining greater values for GM-CSF gene expression in irradiated freshly transfected cells than in high GM-CSF expression clone before irradiation (Fig 6) . Intracellular GM-CSF production was also measured by flow cytometry, employing the GolgiStop procedure. Although there was a decrease in the positive cells percentage (Fig 6a) and in the mean cell fluorescence (Fig 6b) due to cell irradiation (all samples had been previously frozen), these results are 20 times greater than the values for nonirradiated high GM-CSF-secreting clone (data not shown). In the positive cell percentage, a decrease from 33 to 25% was observed. This effect was greater for mean cell fluorescence, falling from 76 to 38 FRU. However, the mice survival results support the idea that even the lower number of positive fresh transfected cells (as a result of cell irradiation and We also measured serum GM-CSF levels by ELISA. The results obtained from wild-type mice and mice vaccinated with nontransfected cells gave rise to no detectable GM-CSF levels (o15 pg/mL). However, serum GM-CSF levels were substantially elevated after mice vaccination with 2 million GM-CSF freshly transfected cells (irradiated and frozen). These GM-CSF levels in serum after 24 and 48 hours were 2208.2777.9 and 51.0731.6 pg/mL, respectively. When we employed cell clones for vaccination, GM-CSF was undetectable in mice serum (o15 pg/mL).
When mice were vaccinated with 0.2 million freshly GM-CSF-transfected cells (days À21, À7 and +7), a significant (two-fold) increase in animal survival was recorded (Po.005). Thus, a significant death delay was achieved between controls and transfected cells, resulting in a 20% final survival at day 90 after tumor challenge (Fig 7) . Apart from the control group of irradiated and nontransfected cells, another group of DOTAP/ pCDNA3-transfected cells was employed, giving rise to a similar animal death pattern for both groups. In additional experiments, we confirmed the efficacy of vaccination with freshly transfected cells. By increasing the dose to 2 million cells per mouse (Fig 8a) , an effective inhibition of tumor growth was achieved, resulting in 100% final mice survival (Po.005). However, a decrease in mice survival was observed (Fig 8b) when using both tissue transfection with 10 mg of GM-CSF plasmid (3 hours before vaccination) plus GM-CSF-transfected cells, yielding a final mice survival of 80% (Po.005). In our previous experiments testing tissue transfection, the expression of GM-CSF was obtained after 48 hours of the treatment (data not shown).
Mice vaccinated with 2 million nontransfected B16 cells yielded a final survival of 20%, although with the 0.2 million cells dose all mice died. These data support the idea that nonviral fresh transfection in tumor cell vaccines could be an appropriate procedure for mediating an efficient antitumor effect.
Immune response to vaccination with freshly transfected cells
In order to analyze humoral response as a result of treatment, we quantified immunoglobulin levels in pooled serum from mice vaccinated with 2 million freshly transfected cells. In a way similar to cell clones therapy, blood samples were collected on days À1 and +15 from tumor challenge (day 0), and the specificity of antitumor IgG antibodies in serum was analyzed by ELISA. Significant increases in ELISA optical density values were observed in all groups with respect to the control (Po.001). The OD increase was higher on day +15 in all groups vaccinated with cells -with B16 (47.4%) and B16-GMCSF (70.0%) -than when employing tissue transfection plus B16 or B16-GMCSF cell vaccines (41.4 Nonviral vector-mediated cell vaccines I Moret-Tatay et al and 56.9%, respectively). All these values were greater than those yielded by cell clones (Fig 5) . In the cases of total IgG, IgG1 and IgG3 subtypes (Fig 9) analyzed by radial immunodiffusion, increased levels were seen in the mice group vaccinated with GM-CSF freshly transfected cells, showing a six-fold increase on day +15 for the IgG3 subtype compared with the controls (Fig 9) . The greatest differences between groups were recorded for IgG2a (Table 1) , the highest levels being obtained in the mice group vaccinated with GM-CSF-transfected cells. However, the immunoglobulin levels decreased when tissue was transfected before GM-CSF cell vaccine injection. These results agree with the decrease in mice survival observed when we employed both tissue pretreatment and GM-CSF cell vaccines (Fig 8) .
Discussion
In the present study, we report that vaccination with nonviral vector-transfected cells can afford up to 100% survival in mice after tumor challenge. The tumor vaccine transfected with DOTAP lipoplexes to express GM-CSF exerted a potent antitumor effect, preventing tumor growth and greatly increasing mice survival (80-100%). This effect was observed employing both stable genetically modified cells (clones) or recently transfected cells (fresh transfection), with a transfection efficiency of X25% using DOTAP/DNA lipoplexes. The antitumor success of these vaccines was similar in all cases involving the use of tumor cells genetically modified to produce GM-CSF. In contrast, similar vaccination strategies with IL-4 genetically modified cells failed to mediate tumor protection. Finally, no synergy was observed when both IL-4-and GM-CSF-modified cells were employed for vaccination.
Referring to the updated results in laboratory studies, the technique of inducing the expression of immune stimulatory genes by tumor cells is being widely applied using viral vectors. 1, 15, [35] [36] [37] In contrast, little work has been reported thus far in the case of cell vaccines engineered by nonviral vectors to secrete cytokines. 38 Our results of vaccination with cells producing GM-CSF offer expectations regarding the promising results obtained by applying nonviral gene therapy, which aims to afford safer therapy despite comparatively lower efficacy. The present study was designed to establish the antitumor efficacy after vaccination of two different cytokines, GM-CSF and IL-4, in genetically modified tumor cells, as cell clones or freshly transfected cells. We chose these cytokines because of their different roles in immune response. GM-CSF seems to afford protective immunity (T-cell memory) and an intense infiltration of immature mononuclear cells. 3, 39 IL-4 is a cytokine that stimulates the proliferation of T cells, B cells and mast cells. 40 It also cooperates with GM-CSF in activating/differentiating dendritic cells. 7 In our experiments, the results show that vaccination with cell clones producing IL-4 did not protect mice from tumor growth, affording tumor protection similar to that obtained with nontransfected B16 wild-type cells. Nevertheless, IL-4 is a cytokine that has been employed in studies with genetically modified cells as vaccines, with disparate results. In this sense, our findings agree with those observed by other authors employing retrovirus-transduced cells, who found a B16-producing GM-CSF-mediated antitumor effect in a B16 brain tumor model, although this effect was not observed when mice were vaccinated with B16 cells secreting IL-4 or with nontransfected B16 cells. 15 However, in other tumors it has been described that vaccination with IL-4-producing cells (viral transduction) could activate tumorkilling mechanisms. 19, 41, 42 The use of cell clones secreting IL-4 did not protect mice from tumor challenge, but cell clones secreting GM-CSF mediated a dose-dependent antitumor response, since 0.2 and 1 million cells yielded a final survival of 80 and 100%, respectively. Cross-priming through the Analyses of IgG2a and IgG2b from mice vaccinated with B16 wild type (nontransfected) or B16 freshly transfected with DOTAP/GM-CSF were carried out. Also represented are the results obtained from an additional experiment of transfected tissue (T.T.) in mouse leg with 10 mg GM-CSF plasmid before vaccination. The control group comprises the nonvaccinated mice. In all cases, the relative SD did not exceed 10%.
Nonviral vector-mediated cell vaccines I Moret-Tatay et al host APCs or direct antigen presentation by the tumor cells is postulated to play an important role in vaccination with GM-CSF, since this cytokine exerts an effect on the maturation of APCs. 6 Since B16 cells do not express H-2 molecules, direct antigen presentation by B16 cells must be a limit mechanism; we therefore speculate that peptides released from tumor cells, employed for vaccination, could prime antitumor response by a cross-priming mechanism.
Since the GM-CSF and IL-4 cytokines have been previously described to play an antineoplastic role, 1, 24 we could hope to increase tumor cell rejection by the combination of genetically modified cells producing IL-4 and GM-CSF. However, we found the greatest antitumor effect when using only GM-CSF-secreting cells, and lower efficacy was observed when both GM-CSF-and IL-4-producing cells were combined for vaccination. This adverse effect could be produced not only by the reduced number of cells employed, but also by a dysregulatory effect of IL-4 on Th1/Th2-activated balance mediated by GM-CSF, resulting in an inhibitory effect on Th1 and reduced CTL response. On evaluating the possible advantages of employing both cytokines, it has been observed that in an intracerebral tumor model, 80% of mice immunized with GM-CSF plus IL-4 transduced B16 cells (viral vectors) rejected an intracerebral tumor cell challenge. 24 These results indicate that when employing a different vaccination model, IL-4 is able to produce a therapeutic effect against tumor challenge (5,000 wildtype cells/mouse).
To confirm that GM-CSF vaccines could produce potent long-lasting antitumor immunity, 1, 43 even through nonviral gene therapy, the cell clone-vaccinated mice that survived wild-type tumor transplantation (6 months previously) were challenged by a second tumor transplant. The latter resulted in a significant reduction in tumor progression and a final survival of 20%. These results can be compared with those of other authors who have obtained similar patterns of response employing viral vectors to transduce cells, and can be interpreted as the establishment of an immunologic memory affording long-term protection against tumor recurrence or metastasis. 1, 4, 17 GM-CSF has been found to be helpful in not only genetically modified tumor cells (clones) but also in fresh cytokine-secreting cells. It is important to point out that it is difficult to keep patient cells in vitro for long periods of time. Thus, evaluation of the vaccination effect of recently transfected cells that are irradiated and kept frozen until vaccination constitutes an important step towards clinical trial application of nonviral gene therapy. With a vaccination dose of 0.2 million cells per mouse, survival in mice was 20%, and increased to 100% with 2 million cells. The modification of the vaccination protocol, including pretreatment of the tissue with 10 mg of GM-CSF plasmid, did not offer advantages -yielding a lesser final survival (80%) in mice when employing 2 million cells. This plasmid tissue pretreatment mediates GM-CSF production by local cells, as determined in previous experiments by qRT-PCR of the tissue (data not shown), but our results indicate that GM-CSF tissue transfection does not increase mice survival. This might reflect that immune stimulation was overexpressed when using GM-CSF-secreting cells plus GM-CSF tissue transfection, resulting in a decrease in tumor rejection. Indeed, it has been demonstrated that the amount of GM-CSF secreted by cell vaccines is critical to the magnitude of the immune response generated. 17, 18 Thus, it might be inferred that if lower levels fail to induce strong antitumor immunity, excessively high levels might produce adverse effects. 24, 44 In addition, we should also consider that the transfected cell types after tissue treatment as well as the time course of cytokine production with respect to antigen presentation could play a role in mediating tolerance rather than immune response stimulation. 45 Different attempts to immunize with irradiated but nontransfected tumor cells have had little success. 1, 46 In our study, the protection of vaccination with wild-type cells had a slight antitumor effect, with a survival of nearly 20% when employing 2 million cells per mouse. This observation agrees with the idea of B16 melanoma as an immunogenic tumor cell line 47 that can produce vitiligo reactions in immunized animals. 48 Almost all the animals in our experiment had vitiligo on the snout, but some also developed a high vitiligo reaction over the rest of the body. With respect to the humoral response, it was shown that GM-CSF elicits an increase in IgG production with the ability to recognize membrane proteins derived from B16 tumor cells. The more significant increases were observed in the cases of IgG3 and IgG2a in freshly transfected cells versus B16 clones, which could explain the success in mice survival of cells secreting GM-CSF. Both immunoglobulin subtypes result from IgG switching induced by IFN-g, mainly produced by Th1-activated cells. In turn, the Th1response is mainly involved in CTL antitumor activity, resulting in increased animal survival. Some authors have observed that the production of IgG2a is associated with a therapeutic response against experimental metastases, although not so in the case of IgG1 induced by IL-4.
14 Cells genetically modified to produce IL-4 had a very limited effect on immunoglobulin production, including the IgG1 subtype. Similar results are reported by other authors, as no differences have been found in terms of an increase in each IgG in serum after treatment with cells producing IL-4. 7 Vaccination with IL-4 was not effective in suppressing tumors, although IL-4 should be necessary to show therapeutic antitumor responses, since on avoiding IL-4 production the number of tumor metastases seem to increase. 49 In conclusion, to our knowledge, this is the first report showing that cell vaccines prepared by nonviral gene therapy procedures can mediate 100% tumor growth prevention. The antitumor efficacy has been observed employing either genetically modified cell clones or fresh transfected cells. Since fresh transfection is a rapid procedure for obtaining genetically modified cells for vaccination, it offers an easy and versatile opportunity to study the antitumor efficacy of different cytokines and their possible synergies. Thus, vaccines based on nonviral gene therapy could be an interesting procedure for clinical applications in human cancer immunotherapy.
